Brief: Akeso Says NMPA Approved NDA Of Ebdarokimab, Il-12/Il-23
21/04/2025 11:27
April 21 (Reuters) - Akeso 9926.HK: NMPA APPROVED NDA OF EBDAROKIMAB, IL-12/IL-23 Further company coverage: 9926.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals